期刊文献+

苍柴调中汤联合沙格列汀对胰岛素抵抗合并肥胖治疗效果观察 被引量:1

Analysis of Effect in Patients with Insulin Resistance and Obesity by Cangchai Tiaozhao DecoctionCombined with Saxagliptin
下载PDF
导出
摘要 目的:探究胰岛素抵抗合并肥胖经苍柴调中汤结合沙格列汀治疗的效果及其糖代谢的影响。方法:选取60例胰岛素抵抗并肥胖的门诊病人,按照随机数表法分为观察组和对照组,每组30例,对照组使用沙格列汀进行治疗,观察组采用苍柴调中汤结合沙格列汀进行治疗,观察比较两组患者的临床疗效、治疗前、后糖代谢指标空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1C)的变化情况以及腰围、体质量指数(BMI)指标的变化情况。结果:观察组患者总有效率(96.67%)明显高于对照组(80.00%),两组比较有统计学意义(P<0.05),治疗前,两组患者的FPG、2 h PG、HbA1C指标比较均无差异(P>0.05),治疗后,观察组患者FPG(5.39±1.59)mmol/L、2 h PG(8.37±1.51)mmol/L、HbA1C[(6.37±1.61)%]均明显低于对照组[(6.83±1.72)mmol/L、(9.41±1.56)mmol/L、[(7.38±1.93)%]],两组比较有统计学意义(P<0.05),治疗前,两组患者的腰围以及BMI指标比较无差异(P>0.05),治疗后,观察组腰围(100.13±7.08)cm以及BMI(27.83±1.02)kg/m2明显低于对照组[(103.97±7.56)cm、(29.64±1.25)kg/m2],两组比较有统计学意义(P<0.05)。结论:苍柴调中汤结合沙格列汀对治疗胰岛素抵抗并肥胖疗效显著,能够有效降低患者的糖代谢水平,改善患者胰岛素抵抗以及肥胖,值得临床推广应用。 Objective:To study the effect in patients with insulin resistance and obesity by Cangchai Tiaozhao Decoction combined with Saxagliptin.Methods:Sixty cases of patients were divided into the observation group(30 cases)and the control group(30 cases).The control group was given Saxagliptin while the observation group received Cangchai Tiaozhao Decoction combined with Saxagliptin.The treatment effect,FPG,2 h PG,HbA1 C,waist circumference and BMI of two groups were compared.Results:Total efficiency(96.67%)of the observation group was significantly higher than the control group’s(80.00%).The difference was statistically significant(P<0.05).FPG,2 h PG and HbA1 C of two groups were not statistically significant(P>0.05)before treatment.FPG(5.39±1.59)mmol/L,2 hPG(8.37±1.51)mmol/L and HbA1 C(6.37±1.61)%of the observation group were significantly lower than the control group’s(6.83±1.72)mmol/L,(9.41±1.56 mmol/L)and(7.38±1.93)%after treatment.The difference was statistically significant(P<0.05).Waist circumference and BMI of two groups were not statistically significant(P>0.05)before treatment.Waist circumference(100.13±7.08)cm and BMI(27.83±1.02)kg/m^2 of the observation group were significantly lower than the control group’s(103.97±7.56)cm and(29.64±1.25)kg/m2 after treatment.The difference was statistically significant(P<0.05).Conclusion:Cangchai Tiaozhao Decoction combined with Saxagliptin had a treatment effect obviously in patients with insulin resistance and obesity.It could effectively reduce the level of glucose metabolism and improve the insulin resistance and obesity.It was worthy of clinical application.
作者 尹冬 惠媛 闵冬雨 王国凤 YIN Dong;HUI Yuan;MIN Dongyu;WANG Guofeng(Department of Endocrine,Xuzhou Medical University Affiliated Hospital of Lianyungang(The First People’s Hospital of Lianyungang),Lianyungang 222000,Jiangsu,China;The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,Liaoning,China)
出处 《中华中医药学刊》 CAS 北大核心 2019年第10期2424-2427,共4页 Chinese Archives of Traditional Chinese Medicine
基金 中国博士后科学基金项目(2014M551121) 辽宁中医药大学脏象理论及应用国家教育部重点实验室开放基金项目(zyzx1705) 连云港市卫生科技项目(201510)
关键词 胰岛素抵抗 肥胖 苍柴调中汤 沙格列汀 糖代谢 insulin resistance obesity Cangchai Tiaozhao Decoction Saxagliptin glucose metabolism
  • 相关文献

参考文献16

二级参考文献218

  • 1荆爱玉,袁晓红,倪红艳,焦阳,梁曦,腾云,谢璇.糖化血红蛋白在诊断2型糖尿病中的价值[J].西安交通大学学报(医学版),2012,33(5):636-639. 被引量:22
  • 2李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 3李红霞,满永,国汉邦,唐蔚青,夏永静,董军,王抒,李健斋.北京市部分人群血压、血糖、血脂异常的知晓率、治疗率和达标率的调查[J].北京医学,2007,29(1):57-57. 被引量:17
  • 4马珺,胡大一,魏毅东,余金明.踝臂指数评价脂代谢异常患者下肢外周动脉病多因素临床研究[J].第四军医大学学报,2007,28(17):1606-1608. 被引量:8
  • 5中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中华糖尿病杂志,2010,2增刊2:1-56.
  • 6Yanai H, Adachi I-I, Hamasaki H, et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis [ J]. J Clin Med Res, 2012,4: 251-258.
  • 7Mohan V, Yang WY, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[J]. Diabetes Res Clin Pract,2009,83: 106-116.
  • 8Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes [ J ]. Diabetes Obes Metab,2010,12:252-261.
  • 9Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2013 [ 2013-06-02 ] . http:/! dx. doi. org/10, 1111/dom. 12128. [ published online ahead of print May 13,2013 ].
  • 10Williams-Herman D, Johnson J,Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotberapy over 2 years in patients with type 2 diabetes [ J ]. Diabetes Obes Metab,2010, 12: 442-451.

共引文献284

同被引文献19

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部